You can buy or sell MOTS and other stocks, options, ETFs, and crypto commission-free!
Motus GI Holdings, Inc. engages in the development and commercialization of the Pure-Vu System to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon. It is a medical technology company dedicated to improving endoscopy outcomes and experiences. Read More The company was founded in September, 2016 and is headquartered in Tirat Carmel, Israel.
Tirat Carmel, Haifa
52 Week High
52 Week Low
Associated PressMar 18
Motus GI Expands Intellectual Property Portfolio with Issuance of New U.S. Patent for the Pure-Vu® System
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Mar 18, 2019--Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, announced today that the U.S. Patent and Trademark Office (USPTO) has issued patent No. 10,179,202 titled, “ Systems and methods for cleaning body cavities and for endoscopic steering,” which protects the Company’s flagship product, the Pure-Vu ® System. The Pure-Vu...
Simply Wall StMar 12
Those Who Purchased Motus GI Holdings (NASDAQ:MOTS) Shares A Year Ago Have A 13% Loss To Show For It
Motus GI Holdings, Inc. (NASDAQ:MOTS) shareholders should be happy to see the share price up 27% in the last quarter. But that doesn’t change the reality of under-performance over the last twelve months. In fact the stock is down 13% in the last year, well below the market return. See our latest analysis for Motus GI Holdings With just US$45,000 worth of revenue in twelve months, we don’t think the market considers Motus GI Holdings to have proven its business plan. You have to wonder why venture capitali...
Associated PressFeb 19
Motus GI Announces Publication of Pure-Vu® System Clinical Study Data in Peer-Reviewed Journal of Clinical Gastroenterology
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Feb 19, 2019--Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, announced today that its manuscript titled, “ , ” has been published in the peer-reviewed . The Company’s flagship product, the Pure-Vu® System, is a U.S. FDA cleared medical device indicated to help facilitate the cleaning of a poorly prepared colon during the colo...
-$0.32 per share
Expected Mar 28, Pre-Market